A united group of investigators at Simon Fraser University in Burnaby.

Most drug-resistance tumor cells develop this unfortunate characteristic due to a drug-pumping protein known as P-glycoprotein. Now, a united group of investigators at Simon Fraser University in Burnaby, British Columbia, is rolling out a microfluidic chip that can trap individual malignancy cells and investigate the ability of various pump-blocking medications to overcome drug level of resistance. This new lab-on-a-chip device could prove useful for learning multiple drug resistance and for selecting the appropriate therapy for a given patient. Related StoriesStudy displays why malignancy anemia therapy stimulates tumor growthDiscovery may open new doors to focusing on how melanoma grows and spreadsUCLA Wellness adopts GenomOncology's GO Clinical Workbench to accelerate analysis for tumor DNA profiling testsPaul Li, Ph.D., and his colleagues developed the dime-size chip to select and retain individual cancers cells within a chamber which can be dosed with medications loaded into an on-chip reservoir.The individual benefits are significant as well – – I believe the product provides patients with a new choice for limb salvage, actually in severe instances where amputation could have been the method of preference. Pegasus Biologics’ Unite Biomatrix materials provides us with a safe, sterile and biologically conductive scaffold with uncompromised power and level of resistance to premature enzymatic degradation while assisting the physiologic healing environment, said Dr. Lee. It’s a material that can be beneficial in a variety of surgical treatments and applications.

Related Posts

Other Posts From Category "hepatology":